Salta al contenuto
Facebook FacebookInstagram InstagramLinkedin LinkedinEmail Email
SITLaB

SITLaB

Società Scientifica Italiana dei Tecnici di Laboratorio Biomedico

AREA PERSONALE
  • Home Page
  • Chi SiamoEspandi
    • Consiglio Direttivo
    • Revisore dei Conti
    • Comitato Scientifico
    • Referenti Regionali
  • Documenti
  • Gruppi di Lavoro
  • News
  • Journal SITLaB News
  • Rivista JBP
  • Campus
  • Social Media
  • Corsi
  • Contatti
AREA PERSONALE
SITLaB
SITLaB
Società Scientifica Italiana dei Tecnici di Laboratorio Biomedico
Facebook Instagram YouTube Linkedin

06/20 Considerazioni pratiche da adottare in un Laboratorio durante la pandemia da COVID -19

Considerazioni pratiche da adottare in un Laboratorio durante la pandemia da COVID -19

Abstract

A severe respiratory disease emerged in the city of Wuhan, Hubei province, China, in December 2019. As of early February 2020, at least 28,088 diagnosed and 24,702 suspected cases have been reported, including at least 564 deaths. Unfortunately, the disease has spread globally. The etiologic agent, a novel coronavirus, now called SARS-CoV-2, was immediately identified and characterized in China. Although we know the presence of unprecedented genetic diversity of viruses in nature, this outbreak further indicates that there is considerable uncertainty in predicting when, where, and how novel disease-causing pathogens emerge. Phylogenetic analyses reveal that SARSCoV-2 is closely related to a group of SARSlike coronaviruses. However, it remains unclear where the virus comes from and how it was transmitted to humans in the first place. Unlike with other zoonotic agents such as hantavirus and arenavirus, thus far we haven’t found a SARS virus in animals that is the same as that in humans. Fortunately, SARS virus has not appeared in humans since 2004. In contrast, this new virus seems to have stronger transmission capabilities among people. Compared to the primary virus in humans, we still know less about whether, what, and how the virus has changed and the effect of the changes for their epidemics in humans. Control and prevention of the disease is especially difficult in China and elsewhere if there are infected individuals with no clinical signs.

Visualizza articolo

Navigazione articoli

Precedente Precedente
05/20 Indicazioni per la valutazione del TLSB
SeguenteContinua
07/20 Stima carichi di lavoro e fabbisogno personale per i TLSB

S.I.T.La.B  Società Scientifica Italiana dei Tecnici di Laboratorio Biomedico
Sede Legale Via Amendola 73 - San Marco in Lamis (FG)
CF: 92289380286
E-mail: info@sitlab.it
PEC: sitlab@arubapec.it

Login socio SITLaB

  • Home Page
  • Chi Siamo
    • Consiglio Direttivo
    • Revisore dei Conti
    • Comitato Scientifico
    • Referenti Regionali
  • Documenti
  • Gruppi di Lavoro
  • News
  • Journal SITLaB News
  • Rivista JBP
  • Campus
  • Social Media
  • Corsi
  • Contatti
Close
  • Home Page
  • Chi Siamo
    • Consiglio Direttivo
    • Comitato Scientifico
    • Revisore dei Conti
  • Documenti
  • Gruppi di Lavoro
  • News
  • Journal SITLaB News
  • Rivista JBP
  • Campus
  • Social Media
  • Corsi
  • Sostieni i nostri progetti
  • Contatti
  • AREA PERSONALE

Scorri in alto
Cerca